Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules
What the future holds
Over the next few years, the global Rheumatoid Arthritis (RA) market is expected to grow from $16.5 billion in 2011 to $23.4 billion in 2016. This expansion of the market will be driven by continued use of existing RA products and introduction of pipeline therapies with less invasive modes of administration. So what are the key factors impacting the current and future changes? And is there room for your product in this crowded arena?
The next five years
Gain instant access to an accurate, unbiased, qualitative review of the latest treatment trends, and five-year quantitative RA market forecast with FirstWord’s Therapy Trends: Rheumatoid Arthritis. This comprehensive FirstWord research is available to you in two modules: KOL Insight and Consensus Outlook.
In addition, both Therapy Trends modules provide you with ‘live’ updates on the potential impact of the latest key market RA events over the next 12 months. You’ll receive these directly, within days of each event’s occurrence.
KOL Insight
KOL Insight Report
Consensus Report
Consensus Outlook: Rheumatoid Arthritis module presents you with a data analysis module, annual historical and forecast product-level sales data from an average of leading equity analysts’ projections
Your Critical Questions Answered
Over the next few years, the global Rheumatoid Arthritis (RA) market is expected to grow from $16.5 billion in 2011 to $23.4 billion in 2016. This expansion of the market will be driven by continued use of existing RA products and introduction of pipeline therapies with less invasive modes of administration. So what are the key factors impacting the current and future changes? And is there room for your product in this crowded arena?
The next five years
Gain instant access to an accurate, unbiased, qualitative review of the latest treatment trends, and five-year quantitative RA market forecast with FirstWord’s Therapy Trends: Rheumatoid Arthritis. This comprehensive FirstWord research is available to you in two modules: KOL Insight and Consensus Outlook.
In addition, both Therapy Trends modules provide you with ‘live’ updates on the potential impact of the latest key market RA events over the next 12 months. You’ll receive these directly, within days of each event’s occurrence.
KOL Insight
KOL Insight Report
- A concise, qualitative KOL analysis of the current and predicted treatment trends, clinical products and commercial changes in the global RA market
- Compare the market’s key players, algorithms, late-stage pipeline drugs, product positioning, and new modes of action
- Access the latest KOL views about possible changes in RA treatment trends, in response to each major RA market event
Consensus Report
- An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key RA market forecast parameters
- Chart RA market size, product sales, market share by company, competitive status and detailed market forecasts
- Review an interactive Excel market analytics module of detailed market and product sales data from 2006 to 2016
Consensus Outlook: Rheumatoid Arthritis module presents you with a data analysis module, annual historical and forecast product-level sales data from an average of leading equity analysts’ projections
Your Critical Questions Answered
- Which key factors are driving RA drugs up the treatment algorithm?
- How are biologics (Orencia, Rituxan, Actemra) affecting the market?
- Could new anti-TNFs (Cimzia, Simponi) threaten first-line Humira?
- How do late-stage pipeline products compare with existing brands?
- What are the unmet clinical needs for RA physicians and patients?
- What strategies are companies using to position new RA agents?
- What are the strengths and flaws of oral, IV and SC arthritis agents?
- How could biosimilars erode current anti-TNF market shares?
- What are the market share forecasts by class and company?
- What will be the key future events that will impact future sales revenue?
- What and when will be the positive and negative events that will impact the market? How will future dynamics in the RA armamentarium unfold compared to historical trends?
- Assess predicted RA market changes
- Evaluate first to fourth-line RA drugs
- Review the threat of biologics and biosimilars
- Analyse expected prescribing trends
- Learn about late-stage pipeline products
- Compare new SC, IV and oral RA drugs
- Track KOL views for the next 12 months
- Evaluate future sales forecasts
- Map your market parameters
- Chart your commercial prospects
- Review predicted market growth
- Assess market share by company
- Compare your competition
- Stay ahead with market data updates
- Business development
- New product planning
- Strategic brand planning
- Market research
- Forecasting and market analytics
- Medical affairs
- Clinical trials
- Relationship management
- Marketing
- Sales
KOL INSIGHTS
EXECUTIVE SUMMARY
INTRODUCTION
METHODOLOGY
CURRENT RHEUMATOID ARTHRITIS MARKETPLACE
Current treatment landscape
Rheumatoid Arthritis market definition
Current market overview
Reimbursement of key Rheumatoid Arthritis brands
UK advisory board’s U-turn for wider use of RA drugs
Unmet needs in Rheumatoid Arthritis
Unmet need 1: More efficacious therapies
Unmet need 2: Personalised medicine
Unmet need 3: Earlier diagnosis for treatment
Unmet need 4: Cheaper therapies
Unmet need 5: Improved safety profile
Unmet need 6: Drugs to halt or reverse damage
Unmet need 7: Improved mode of administration
CURRENT RHEUMATOID ARTHRITIS THERAPIES
Pivotal trial data of approved therapies
Anti-TNF therapies
Enbrel (etanercept; Amgen/Pfizer/Takeda) treatment trends
Humira (adalimumab; Abbott/Eisai) treatment trends
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Cimzia (certolizumab; UCB) treatment trends
Other biologic therapies
Orencia (abatacept) treatment trends
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/ Chugai) treatment trends
Actemra/RoActemra (tocilizumab; Chugai/Roche) treatment trends
Current treatment algorithm
Methotrexate: the first-line therapy of choice
Anti-TNFs: second-line RA therapies
The commercial challenge of RA drug switching
Beyond TNF-inhibitors: second and third-line therapies
FUTURE RHEUMATOID ARTHRITIS THERAPIES
Future treatment landscape
Tofacitinib (CP-690,550; Pfizer/Takeda) treatment trends
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) treatment trends
Secukinumab (AIN457; Novartis) treatment trends
More aggressive, earlier treatment
Tofacitinib: expanded use as experience rises
Numerous treatment options may confuse prescribers and patients
FUTURE DEVELOPMENTS IN RHEUMATOID ARTHRITIS
Novel targets in the treatment of rheumatoid arthritis
Biosimilar threat is imminent
Eventual development of biomarkers will aid treatment
Patient recruitment will be harder for developers
Clinical trials will have to evolve in the future
FIRSTWORD RHEUMATOID ARTHRITIS NEWS ANALYSIS
Positive Rheumatoid Arthritis key news events
Current therapies
Pipeline therapies
Company therapies
Negative Rheumatoid Arthritis key news events
Marketed therapies
Pipeline therapies
Company therapies
APPENDIX 1
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX 2
Links to Rheumatoid Arthritis News Stories Jan 2011-May 2012
CONSENSUS OUTLOOK
INTERACTIVE DATA ANALYSIS FILE (EXCEL)
TABS:
Market size
Product sales
Company forecast
Mechanism of action
Events
MARKET ANALYSIS FILE (PDF)
CONTENTS:
FirstWord Analysis Highlights
Rheumatoid Arthritis marketplace
Key Rheumatoid Arthritis developers
Rheumatoid arthritis class dynamics
Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
Humira (adalimumab; Abbott/Eisai) forecast
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./ Mitsubishi Tanabe) forecast
Cimzia (certolizumab; UCB) forecast
Orencia (abatacept; Bristol-Myers Squibb) forecast
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
Secukinumab (AIN457; Novartis) forecast
EXECUTIVE SUMMARY
INTRODUCTION
METHODOLOGY
CURRENT RHEUMATOID ARTHRITIS MARKETPLACE
Current treatment landscape
Rheumatoid Arthritis market definition
Current market overview
Reimbursement of key Rheumatoid Arthritis brands
UK advisory board’s U-turn for wider use of RA drugs
Unmet needs in Rheumatoid Arthritis
Unmet need 1: More efficacious therapies
Unmet need 2: Personalised medicine
Unmet need 3: Earlier diagnosis for treatment
Unmet need 4: Cheaper therapies
Unmet need 5: Improved safety profile
Unmet need 6: Drugs to halt or reverse damage
Unmet need 7: Improved mode of administration
CURRENT RHEUMATOID ARTHRITIS THERAPIES
Pivotal trial data of approved therapies
Anti-TNF therapies
Enbrel (etanercept; Amgen/Pfizer/Takeda) treatment trends
Humira (adalimumab; Abbott/Eisai) treatment trends
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Cimzia (certolizumab; UCB) treatment trends
Other biologic therapies
Orencia (abatacept) treatment trends
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/ Chugai) treatment trends
Actemra/RoActemra (tocilizumab; Chugai/Roche) treatment trends
Current treatment algorithm
Methotrexate: the first-line therapy of choice
Anti-TNFs: second-line RA therapies
The commercial challenge of RA drug switching
Beyond TNF-inhibitors: second and third-line therapies
FUTURE RHEUMATOID ARTHRITIS THERAPIES
Future treatment landscape
Tofacitinib (CP-690,550; Pfizer/Takeda) treatment trends
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) treatment trends
Secukinumab (AIN457; Novartis) treatment trends
More aggressive, earlier treatment
Tofacitinib: expanded use as experience rises
Numerous treatment options may confuse prescribers and patients
FUTURE DEVELOPMENTS IN RHEUMATOID ARTHRITIS
Novel targets in the treatment of rheumatoid arthritis
Biosimilar threat is imminent
Eventual development of biomarkers will aid treatment
Patient recruitment will be harder for developers
Clinical trials will have to evolve in the future
FIRSTWORD RHEUMATOID ARTHRITIS NEWS ANALYSIS
Positive Rheumatoid Arthritis key news events
Current therapies
Pipeline therapies
Company therapies
Negative Rheumatoid Arthritis key news events
Marketed therapies
Pipeline therapies
Company therapies
APPENDIX 1
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX 2
Links to Rheumatoid Arthritis News Stories Jan 2011-May 2012
CONSENSUS OUTLOOK
INTERACTIVE DATA ANALYSIS FILE (EXCEL)
TABS:
Market size
Product sales
Company forecast
Mechanism of action
Events
MARKET ANALYSIS FILE (PDF)
CONTENTS:
FirstWord Analysis Highlights
Rheumatoid Arthritis marketplace
Key Rheumatoid Arthritis developers
Rheumatoid arthritis class dynamics
Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
Humira (adalimumab; Abbott/Eisai) forecast
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./ Mitsubishi Tanabe) forecast
Cimzia (certolizumab; UCB) forecast
Orencia (abatacept; Bristol-Myers Squibb) forecast
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
Secukinumab (AIN457; Novartis) forecast
FIGURES:
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Growth and market share of the US and international RA markets, 2006–16
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Rheumatoid Arthritis worldwide market share difference from 2006 to 2016
Rheumatoid Arthritis worldwide market sales value split by class, 2011
Sales dynamics of leading Alzheimer’s disease brands, 2011-2016
Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016
Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide ($m), 2006–2016
Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016
Humira (adalimumab; Abbott/Eisai) sales by region worldwide ($m), 2006–2016
Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2006–2016
Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2009–2016
Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016
Cimzia (certolizumab; UCB) sales by region worldwide ($m), 2009–2016
Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016
Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide ($m), 2009–2016
Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide ($m), 2009–2016
Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016
Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide ($m), 2009–2016
Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016
Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide ($m), 2012–2016
Sales dynamics of fostamatinib disodium (R788), 2011-2016
Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016
Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016
Secukinumab (AIN457; Novartis) sales by region worldwide ($m), 2014–2016
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Growth and market share of the US and international RA markets, 2006–16
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Rheumatoid Arthritis worldwide market share difference from 2006 to 2016
Rheumatoid Arthritis worldwide market sales value split by class, 2011
Sales dynamics of leading Alzheimer’s disease brands, 2011-2016
Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016
Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide ($m), 2006–2016
Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016
Humira (adalimumab; Abbott/Eisai) sales by region worldwide ($m), 2006–2016
Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2006–2016
Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2009–2016
Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016
Cimzia (certolizumab; UCB) sales by region worldwide ($m), 2009–2016
Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016
Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide ($m), 2009–2016
Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide ($m), 2009–2016
Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016
Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide ($m), 2009–2016
Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016
Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide ($m), 2012–2016
Sales dynamics of fostamatinib disodium (R788), 2011-2016
Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016
Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016
Secukinumab (AIN457; Novartis) sales by region worldwide ($m), 2014–2016
TABLES:
Sales and growth of regions for Rheumatoid Arthritis, 2011–2016
Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016
Sales and growth of classes in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of secukinumab (AIN457; Novartis) in Rheumatoid Arthritis, 2014–2016
Sales and growth of regions for Rheumatoid Arthritis, 2011–2016
Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016
Sales and growth of classes in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of secukinumab (AIN457; Novartis) in Rheumatoid Arthritis, 2014–2016
